Medical/Pharmaceuticals
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that CT041, an autologous CAR T-cell product candidate against...
2022-03-23 20:50
2486
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies
SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 Annual Results. Business Highlights * CT053: complete...
2022-03-23 20:50
4340
Smartee Raises US$ 80 Million in Series D Funding
BEIJING, March 23, 2022 /PRNewswire/ -- In March 2022, Smartee announced that it has closed its Series D funding round ofUS$ 80 million. This round of financing was led by Beijing Taikang Investment, followed by China Resources Consumer Fund II, Jiaxing Science City, Zhangjiagang Industrial Inves...
2022-03-23 20:40
3177
InnoCare Releases 2021 Annual Results and Business Highlights
BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...
2022-03-23 08:08
3905
VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease
SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients wi...
2022-03-23 08:00
2501
Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively
The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...
2022-03-23 06:53
4035
WuXi Biologics Achieved Record Growth and Profitability in 2021
Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...
2022-03-23 00:38
3775
INDICAID COVID-19 Rapid Antigen At-Home Test Receives FDA Emergency Use Authorization (EUA) for Over-the-Counter (OTC), Asymptomatic, Non- Prescription Use
GARDEN GROVE, Calif., March 22, 2022 /PRNewswire/ -- PHASE
Scientific International, LTD
2022-03-23 00:00
2599
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...
2022-03-22 22:50
2910
NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood
OSAKA, Japan, March 22, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (hereinafter NIBIOHN) based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood (serum and plasma). Us...
2022-03-22 14:00
1764
OBiO Technology Goes Public on Shanghai Stock Exchange Today
SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238). Founded in 2...
2022-03-22 13:00
3593
INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA
HANGZHOU, China, March 21, 2022 /PRNewswire/ -- Broncus(02216HK) today is pleased to announce that InterVapor® (including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), the Company's thermal vapor treatment system, has been granted approval by the National Medical Products Adm...
2022-03-22 10:34
2397
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
SUZHOU, China, and ROCKVILLE, MD, March 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor, alrizomadlin ...
2022-03-22 09:15
2454
Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain
SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced successful results in its Phase IIb study of its perioperative long-acting anal...
2022-03-22 00:00
2258
Ascentage Pharma Announces 2021 Annual Results with Commercialization Programs Going Full Steam Ahead
SUZHOU, China and ROCKVILLE, Md., March. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today released its annual results for full year 2021, during whi...
2022-03-21 23:11
3470
BIOKANGTAI Signs a Cooperation Agreement with the Largest Importer of Parenteral Products in Philippines
SHENZHEN, China, March 21, 2022 /PRNewswire/ -- On March 17, 2022, Shenzhen Kangtai Biological Products Co., Ltd signed a framework agreement with Phil.PharmaWealth Inc., the largest importer of Parenteral Products in Philippines, and both parties reached an agreement on jointly promoting the reg...
2022-03-21 22:22
2632
3billion to reveal its diagnostic performance at ACMG annual meeting 2022
SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- 3billion announced that Chief Medical Officer Dr.Go Hun Seo will introduce a research poster at ACMG annual meeting 2022, held inNashville, TN, from March 22 through 26. This poster highlights the importance of continuous reanalysis for undiagnos...
2022-03-21 22:00
2501
ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research
BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science company with the mission of characterizing commercially av...
2022-03-21 20:15
2262
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a c...
2022-03-21 20:00
2584
KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Scientific Meeting ...
2022-03-21 20:00
3470
Week's Top Stories
Most Reposted
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
[Picked up by 324 media titles]
2026-07-24 12:00
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 308 media titles]
2026-07-30 10:45
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
[Picked up by 295 media titles]
2026-07-24 18:32
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
[Picked up by 292 media titles]
2026-07-24 16:25
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 291 media titles]
2026-07-30 15:00Most Read
Visa and Lianlian Advance Trusted B2B Agentic Commerce Through LoopXPay's First Live B2B Agentic Transaction
2026-07-24 12:00
14179
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
2026-07-23 16:00
14092
Phuket Marriott Resort & Spa, Merlin Beach Elevates Guest Experience with New Dining and Family Facilities
2026-07-24 18:32
12835
Courtyard by Marriott Phuket, Patong Beach Wins TripAdvisor Best of the Best Award
2026-07-24 16:25
11780